Analysts fell to the sidelines weighing in on Arrowhead Pharmaceuticals (ARWR – Research Report), Waters (WAT – Research Report) and Bristol-Myers Squibb (BMY – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Arrowhead Pharmaceuticals (ARWR)
In a report released yesterday, Mani Foroohar from Leerink Partners reiterated a Hold rating on Arrowhead Pharmaceuticals, with a price target of $28.00. The company’s shares closed last Tuesday at $33.20.
According to TipRanks.com, Foroohar is a 1-star analyst with an average return of
Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Moderate Buy with an average price target of $53.20, which is a 66.6% upside from current levels. In a report released today, Citi also assigned a Hold rating to the stock with a price target.
See Insiders’ Hot Stocks on TipRanks >>
Waters (WAT)
In a report released today, Daniel Arias from Stifel Nicolaus maintained a Hold rating on Waters, with a price target of $330.00. The company’s shares closed last Tuesday at $330.38, close to its 52-week high of $346.24.
According to TipRanks.com, Arias is ranked 0 out of 5 stars with an average return of
Waters has an analyst consensus of Hold, with a price target consensus of $310.27, which is a -3.6% downside from current levels. In a report issued on January 29, Robert W. Baird also maintained a Hold rating on the stock with a $289.00 price target.
Bristol-Myers Squibb (BMY)
Leerink Partners analyst David Risinger assigned a Hold rating to Bristol-Myers Squibb on February 2 and set a price target of $51.00. The company’s shares closed last Tuesday at $49.26, close to its 52-week low of $47.58.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol-Myers Squibb with a $57.79 average price target, representing a 20.5% upside. In a report released yesterday, Redburn Atlantic also downgraded the stock to Hold with a $54.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARWR:
- ARWR Upcoming Earnings Report: What to Expect?
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential
- Arrowhead price target raised to $62 from $59 at Piper Sandler
- Arrowhead 15.8M share Secondary priced at $28.50
